0002014596-26-000044
SEC filingConcentra delivered strong double-digit revenue and earnings growth in Q1 2026, driven by organic expansion and acquisitions, with improved cash flow and margin expansion.
Concentra's revenue increased 13.7% year-over-year to $569.6 million, reflecting a combination of organic growth and contributions from recent acquisitions. Management attributed the top-line expansion to higher patient volumes and the addition of new centers, including the Nova acquisition completed in early 2025. The company's occupational health centers and onsite health clinics both contributed to the growth, though specific segment breakdowns were not provided in the filing. The revenue growth outpaced the increase in cost of services, which rose at a slower rate due to improved staffing efficiencies, as noted in management's discussion.
Net income rose 29.8% to $50.5 million, and diluted earnings per share increased 30.0% to $0.39. The bottom-line growth benefited from the operating income improvement and a lower effective tax rate compared to the prior year. The EPS growth was slightly higher than net income growth due to a modest reduction in diluted shares outstanding, though share repurchase activity was not quantified in the filing.
Net cash provided by operating activities nearly doubled to $21.0 million, driven by higher net income and favorable working capital changes. Capital expenditures decreased to $11.1 million from $15.7 million in the prior year, reflecting a normalization after growth investments in 2025. Free cash flow improved to $9.9 million, providing flexibility for strategic investments and capital returns. Management noted that the increase in net working capital surplus was principally due to an increase in accounts receivable, partially offset by a decrease in cash from share repurchases.
Concentra maintains a strong liquidity position, with internally generated cash flows and borrowing capacity under its Revolving Credit Facility expected to finance operations in both the short and long term. The company's primary source of cash is the collection of accounts receivable, which is critical to liquidity and capital resources. Management uses Adjusted EBITDA and Adjusted EBITDA margin to evaluate financial performance and determine resource allocation across operating segments.
While historical results are not necessarily indicative of future performance, Concentra's Q1 results demonstrate the effectiveness of its growth strategy and operational efficiency initiatives. The company continues to focus on organic expansion through patient volume growth and strategic acquisitions, while maintaining disciplined capital allocation. There is no assurance that future dividends will be declared, but the company's cash flow generation supports ongoing investment in the business.